Лучшие больницы для «Aortic Stenosis Treatment» в Хайдарабад, Индия

The total cost of aortic stenosis treatment depends on the specific procedure chosen — TAVR (transcatheter) or SAVR (surgical) — the prosthetic valve selected, and the patient's individual clinical complexity. In India, at JCI- and NABH-accredited cardiac centres, the all-inclusive cost for TAVR typically ranges from USD 10,000 to USD 18,000, while conventional surgical aortic valve replacement (SAVR) ranges from USD 7,000 to USD 14,000. These figures include the prosthetic valve and implant materials, cardiac ICU stay, ward stay, standard medications, anaesthesia, and a pre-discharge echocardiogram. In the UAE (Dubai and Abu Dhabi), at JCI- and DHA-accredited institutions, the equivalent cost ranges from USD 22,000 to USD 40,000 for TAVR and USD 18,000 to USD 30,000 for SAVR, reflecting the premium infrastructure, operating costs, and specialist fees of the Gulf region. Both destinations offer a cost saving of 50–75% compared to equivalent procedures in the United States (where TAVR alone exceeds USD 80,000–100,000) or Western Europe. GAF Healthcare provides a fully transparent, itemised cost estimate specific to your diagnostic profile before any financial commitment — covering all procedural, hospital, and associated non-medical logistics costs, with no hidden facilitation charges to the patient.

The duration of in-country stay before you are medically cleared for international air travel depends primarily on whether you undergo TAVR or surgical aortic valve replacement (SAVR), and on your individual post-procedural recovery course. For TAVR via the transfemoral route, the typical hospital stay is 3–5 days. Most TAVR patients who have an uncomplicated procedure — no permanent pacemaker requirement, no neurological event, stable haemodynamics, and a healed femoral access site — are declared fit-to-fly by the treating cardiologist approximately 2–3 weeks after the procedure. This allows time for a 7-day post-discharge outpatient review with echocardiogram and ECG, and ensures that any delayed conduction disturbances or early valve thrombosis have been identified. For SAVR, the hospital stay is 7–10 days, and the sternal wound, pleural healing, and volume status require a longer period of monitoring. SAVR patients are typically cleared for long-haul international flight 5–6 weeks post-procedure. Patients with a permanent pacemaker implanted post-TAVR require a device check at 4–6 weeks before air travel. Patients with new-onset atrial fibrillation post-SAVR require therapeutic anticoagulation and rhythm stability before flying. GAF Healthcare's treating cardiologist issues a formal medical fitness-to-fly certificate, along with an in-flight medical briefing note for the airline, before your departure is confirmed. We strongly advise against self-discharge or premature travel, as the haemodynamic changes at cabin altitude and the risk of deep vein thrombosis on long-haul flights are clinically significant in the early post-operative period.

At GAF Healthcare's high-volume partner centres in India and the UAE, procedural success rates for aortic stenosis intervention are 95–98%, consistent with outcomes reported by leading global structural heart programmes. For TAVR specifically, 'device success' — defined by the Valve Academic Research Consortium-2 (VARC-2) criteria as successful vascular access, delivery, and deployment of the valve in the correct anatomical position, with only trace or mild paravalvular regurgitation and a post-procedural mean gradient of less than 20 mmHg — is achieved in over 97% of procedures at our partner centres. The 30-day all-cause mortality for isolated TAVR in low-to-intermediate risk patients at these institutions is below 2%, mirroring landmark trial data from PARTNER 3 and Evolut Low Risk. For surgical aortic valve replacement (SAVR) in low-risk patients (STS-PROM below 4%), 30-day mortality is 1–2%. At 1 year, freedom from all-cause mortality post-TAVR exceeds 90% in intermediate-risk cohorts, and post-SAVR, 10-year survival with a tissue bioprosthesis is approximately 60–70% (heavily influenced by patient age and comorbidities rather than valve-related failure). Structural valve deterioration requiring re-intervention is rare within the first 8–10 years for modern pericardial bioprostheses. It is important to understand that 'success rate' encompasses both the procedural technical success and longer-term haemodynamic and clinical outcomes — both of which are systematically tracked and reported by GAF's partner institutions through mandatory institutional quality registries and follow-up programmes. Your specific outcome probability will be individualised by the treating Heart Team based on your STS-PROM score, EuroSCORE II, MSCT anatomy, frailty assessment, and comorbidity profile during the pre-procedural teleconsultation with GAF Healthcare.